Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994850 | 0.87 | ICMT (0.46) | F2PRSS1IDO1ALDH1A1L3MBTL1 | |
| SCHEMBL1992845 | 0.84 | CHRM2 (0.48) | F2PRSS1IDO1KDM4EHTR6 | |
| SCHEMBL1994166 | 0.83 | MEN1 (0.47) | F2PRSS1IDO1ALDH1A1L3MBTL1 | |
| SCHEMBL30979650 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KMT2AKDM4EMAPTGFER | |
| SCHEMBL13348961 | 0.76 | IDO1 (0.58) | IDO1ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL29982985 | 0.73 | ALDH1A1 (0.65) | IDO1ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL450556 | 0.72 | MEN1 (0.46) | KMT2AMEN1GAA | |
| SCHEMBL2636547 | 0.70 | MEN1 (0.68) | ALDH1A1L3MBTL1KMT2AMEN1GAA | |
| SCHEMBL6177917 | 0.70 | CYP2C9 (0.57) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL18043819 | 0.70 | CYP2C9 (0.50) | ALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | F2 1048/4885PRSS1 1370/4885IDO1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.